Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Hims Hers Health

What's Going On With Hims & Hers Health Stock Today?

Hims Hers Health Inc (NYSE:HIMS) shares surged in early trading Wednesday before pulling back. The stock was still up marginally at last check after the company announced a planned Canadian expansion.

What's Going On With Hims & Hers Health Stock Today?

What's Going On With Hims & Hers Health Stock Today?

Hims Hers Health Inc. (NYSE:HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after selling off to start the week. Here’s a look at what you need to know.

Why Did Novo Nordisk Pull the Plug on Hims Collaboration?

Why Did Novo Nordisk Pull the Plug on Hims Collaboration?

Novo Nordisk ended its partnership with Hims & Hers on 23 June 2025, accusing the telehealth firm of selling unsafe, unapproved Wegovy knock-offs. Hims' stock tanked, and legal risks loom.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Hims & Hers Health Stock Is Tumbling Monday: What's Happening?

Hims Hers Health Inc (NYSE:HIMS) shares are trading lower Monday after Novo Nordisk A/S (NYSE:NVO) terminated its collaboration with the company.

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

Hims & Hers: From Viral Ad to Volatile Stock

Hims & Hers leverages its viral Super Bowl advertisement and strategic weight loss market entry to achieve stock gains and brand recognition in telehealth.

Where Hims & Hers Health Stands With Analysts

Analysts' ratings for Hims Hers Health (NYSE:HIMS) over the last quarter vary from bullish to bearish, as provided by 10 analysts.

inkl

Read news from The Economist, FT, and more,
with one subscription

Spotlight on Hims & Hers Health: Analyzing the Surge in Options Activity

Spotlight on Hims & Hers Health: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bullish approach towards Hims Hers Health (NYSE:HIMS), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HIMS usually suggests something big…

Exclusive: The COO of Hims & Hers was the third person to try their GLP-1 drugs—and she's ready to share her story

Exclusive: The COO of Hims & Hers was the third person to try their GLP-1 drugs—and she's ready to share her story

Health executive Melissa Baird is dedicated to breaking the stigma of weight management at work.

Is Hims & Hers Stock a Buy for GLP-1 Upside?

Is Hims & Hers Stock a Buy for GLP-1 Upside?

Hims & Hers is a digital health company that is firing on all cylinders, while improving its profit margins at a robust pace.

Stock Market Today: Stocks Rise as Fed Speakers Speak and Nvidia Awaits

Stock Market Today: Stocks Rise as Fed Speakers Speak and Nvidia Awaits

Markets eked out gains in a low-volume session that was more focused on upcoming earnings from NVDA.

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022

Get all your
news in one place.

100's of premium titles.
One news app.

3 Stocks Under $5 Insiders Are Aggressively Buying

U.S. stocks closed sharply lower, with the Nasdaq Composite dipping around 450 on Thursday. Investors, meanwhile, focused on some notable insider trades.

Hims & Hers Health's Return On Capital Employed Overview

According to Benzinga Pro data, during Q1, Hims & Hers Health (NYSE:HIMS) posted sales of $101.31 million. Earnings were up 47.85%, but Hims & Hers Health still reported an overall loss of $16.25 million.

Earnings Preview For Hims & Hers Health

Hims & Hers Health (NYSE:HIMS) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Hims & Hers Health will report an earnings per share (EPS) of $-0.07.

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

Get all your
news in one place.

100's of premium titles.
One news app.

1 2

People

Philip Jefferson

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Electronic Arts

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

364,948 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play